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TECHNICAL NOTE
Staining of bone for aluminum: Use of acid solochrome azurine
MICHAEL KAYE, ANTHONY B. HODSMAN, and LYDIA MALYNOWSKY
Division of Nephrology, Montreal General Hospital, Montreal, Quebec and The Research Institute, St. Joseph's Health Centre, London,
Ontario, Canada
Aluminum is now recognized as a major cause of bone
disease in patients on long term dialysis [1, 2]. The use of a
simple staining technique using ammonium azurine tricarboxy-
lie acid (aluminon), has been invaluable for the recognition of
aluminum deposited in bone [3, 4]. Although not specific, in
practice the only other metal likely to give a positive result is
iron, which can be readily identified by staining another section
for iron using the Prussian blue reaction [5]. While chemical and
other physical techniques are required to validate a histochem-
ical stain, reports that the aluminon method is a better indicator
of bone histology and function than is the analyzed bone
aluminum content have strengthened dependence on the use of
this staining method [6, 7].
In 1984, Denton, Freemont and Ball compared aluminon with
two other staining techniques and showed that acid solochrome
azurine (ASA) gave more intense staining than aluminon and
correlated well with analyzed bone aluminum values and elec-
tron probe analysis [8]. We have noted that, on occasion,
unexpectedly low and misleading results have been found with
the aluminon stain. The present study addresses the reliability
and usefulness of the two techniques using quantitative histo-
morphometry.
Methods
Undecalcified iliac crest trephine biopsies were processed as
described previously [9, 10]. In brief, after embedding in glycol
methacrylate (GMA), 2 sm thick sections were cut with glass
knives for histology and 4 or 8 m sections for aluminum
staining. Routine sections were stained for acid phosphatase
and counterstained with Harris hematoxylin. The aluminon
stain was done using both previously described methods [3, 41
on 4 pm sections. As well, we used the Maloney specifications,
but at 37°C for two hours of 8 tm sections instead of 68°C for 10
minutes. This is our standard technique. The effect of buffer pH
was compared using pH 5.6 instead of the recommended 5.2. In
addition to GMA embedded material we also examined sections
in methyl methacrylate (MMA) and Spurr. The effect of heat
was examined by placing the unstained section on glass slides
which were left in the oven at 95°C for 18 hours. Control
sections were unheated and both were stained simultaneously.
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The time when the effect of the heat became apparent was
looked for using serial sections heated for 1, 3, 6, 9, 12, 18, 24,
48 and 72 hours. In some MMA sections the plastic was
removed by pre-treatment with cellusolve and subsequently
stained with aluminon and compared with simultaneously
stained sections with intact plastic. Staining with ASA was
carried out as described previously [8] in GMA, MMA and
Spurr, both heated and unheated. Eight micrometer sections
were stained for 18 hours at room temperature in 1% aqueous
solochrome azurine acidified to pH 5.0 with 25% acetic acid just
prior to use. They were differentiated for 20 minutes in 95%
methanol, rinsed, dried and mounted. Samples from subjects
without renal failure were invariably negative with both alumi-
non and ASA stains. The Prussian blue reaction was used for
stainable iron and visually scored as present or absent. Mor-
phometry was performed using a Zeiss MOP-3 projection
system as previously characterized [101. Irrespective of their
aluminum status the patients were divided into six categories
based on the morphometric data: Group 1, normal bone; Group
2, hyperparathyroid, if the osteoclasts (OC) were 0.3/mm tra-
becular surface or more and the bone formation rate (B FR) 400
sm2/day/mm2 or more; Group 3, osteomalacia, if the BFR was
250 tm2/day/mm2 or less and if osteoid surface (Ost/s) was 55%
or more or osteoid thickness (Ost) was 20 pm or more; Group
4, aplastic, if the BFR was 250 sm2/day/mm2 or less and Ost/s
was 55% or less or Ost 12 jm or less. Group 5 showed mixed
features of both hyperparathyroidism and osteomalacia and
Group 6 was abnormal but non-specific. Aluminum staining was
expressed either as percent trabecular (mineralized plus osteoid
surface) or percent area of either bone (mineralized plus os-
teoid) or total tissue (bone plus marrow space). Quantitation
was performed at both X 72 and X 183 magnification with
similar results. From among some 400 biopsies 25 cases were
selected that covered a wide range of measured bone aluminum
content from normal to very high. Excluded were patients who
had not been suitably labelled with tetracycline, were on
steroids, had diabetes or had been receiving deferoxamine
therapeutically, or were on dialysis for less than one year. Bone
aluminum content (BAC) was measured in 14 individuals, on a
sample of cortical bone from the same biopsy, in London,
Ontario using flameless atomic absorption spectrometry. Nor-
mal values are less than 20 mg/kg dry bone [2]. These results
can be compared to those found in our previous study [10]. In
the remaining 11 patients cortical bone aluminum was measured
in Quebec City (Centre de Toxicologie du Québec, Centre
Hospitalier de I'Universitd Lava!, Ste-Foy, Québec). These
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Table 1. Histomorphometiy
Case
no.
Group
no.
Bone
area Ost/s T/S
OC/
mm
Ost
un
Ostla
%
BAC
mgi
kg
Al/s ASA/s ASA/a Iron
m b
DLT
%
BFR
iLm2l
day!
mm2
MLT
day
AR
.wn/
day%%
1 1 19.6 17.8 6.1 0.1 10.6 3.2 11.0 0.0 0.0 0.0 + — 0.3 289 3.9 2.2
2 2 32.5 61.6 20.5 0.6 17.6 13.5 240.8 42.2 70.5 28.4 — — 6.9 433 4.8 2.9
3 2 24.7 30.0 23.5 0.6 15.2 6.6 115.6 18.0 66.2 28.5 + — 4.2 609 11.2 1.1
4 2 24.7 60.5 48.1 0.5 12.3 9.8 185.3 2.5 31.7 12.8 — — 8.8 1737 6.7 1.5
5 2 26.2 62.7 45.7 0.7 15.1 13.2 185.3 7.0 55.0 21.0 — — 7.8 2245 6.6 1.8
6 2 19.7 60.3 38.9 0.4 13.9 14.2 20.8 0.0 0.0 0.0 + — 1.6 600 15.6 0.7
7 2 31.1 22.0 15.0 0.9 17.6 6.0 111.2 4.0 64.0 46.2 -- — 10.2 1464 8.8 1.6
8 2 43.9 68.0 54.3 0.5 19.6 12.4 37.1 0.0 4.9 0.6 + — 21.0 4325 7.0 2.2
Mean 29.0 52.1 35.1 0.6 15.9 10.8 128.0 10.5 41.8 19.6 8.6 1631 8.7 1.7
3.0 6.9 6.0 0.1 1.0 1.3 30.7 5.8 11.2 6.3 2.3 517 1.4 0.3
9 3 26.2 57.5 0.0 0.3 26.4 23.9 198.0 73.0 73.2 57.9 4- — 0.0 0 0.0 0.0
10 3 25.9 85.5 5.2 0.1 28.2 31.5 117.6 52.0 72.1 39.2 + — 1.6 108 30.3 0.7
11 3 42.2 92.4 0.0 0.2 67.7 67.8 55.6 39.6 80.6 29.9 4- + 0.0 0 0.0 0.0
12 3 20.1 57.1 3.3 0.2 12.6 11.1 12.0 34.4 52.1 11.5 + — 0.0 0 0.0 0.0
13 3 35.8 56.1 4.6 0.2 17.6 13.6 78.0 34.0 73.0 32.7 4- — 0.0 0 0.0 0.0
14 3 19.1 80.3 7.0 0.2 14.4 25.1 110.0 38.0 77.3 43.3 -- — 0.2 221 9.7 1.2
15 3 26.5 55.2 0.1 0.2 13.7 10.9 283.6 68.7 93.1 68.3 + + 0.0 0 0.0 0.0
Mean 28.0 69.2 2.9 0.2 25.9 26.3 122.1 48.5 74.5 40.4 0.3 47 6.9 0.3
3.1 6.1 1.1 0.0 7.4 7.5 34.7 6.2 6.6 7.1 0.2 33 4.2 0.2
16 4 46.1 58.0 7.1 0.2 8.0 5.9 259.4 14.9 65.8 25.9 -- — 0.5 217 8.3 0.8
17 4 22.3 28.1 1.5 0.1 10.6 6.0 203.8 3.6 60.2 37.8 + — 0.6 51 9.6 0.9
Mean 34.2 43.1 4.3 0.2 9.2 6.0 231.6 9.3 63.8 31.9 0.5 134 8.3 0.8
11.9 15.0 2.8 0.0 1.2 0.1 27.8 5.7 2.8 6.0 0.0 83 1.3 0.0
18 5 22.4 50.5 13.3 0.3 15.2 9.7 222.4 26.9 69.7 50.4 + — 1.2 157 19.8 0.6
19 5 18.1 39.5 28.3 0.5 13.6 7.7 31.3 0.0 1.1 0.0 + — 0.4 203 24.7 0.4
20 5 32.6 72.5 60.0 1.1 27.9 27.5 129.7 0.0 34.3 19.4 + — 15.5 1196 35.0 0.6
21 5 26.8 68.9 33.1 0.6 7.5 7.0 296.5 25.7 63.2 53.0 — — 10.1 1178 5.0 1.2
22 5 33.6 53.7 31.2 0.8 23.4 16.0 74.6 1.0 73.0 27.0 + — 0.1 692 22.5 0.8
23 5 29.5 68.5 9.6 0.4 15.5 13.4 203.8 24.0 65.8 22.0 — — 2.7 622 5.7 2.2
24 5 40.9 63.4 26.5 0.5 21.4 14.9 192.4 28.0 64.2 38.2 + — 1.5 859 15.6 1.1
Mean 29.1 59.1 28.9 0.6 17.8 13.7 164.4 15.1 53.0 30.0 4.5 701 18.3 1.0
2.9 4.4 6.2 0.1 2.6 2.3 34.6 5.2 9.9 7.1 2.3 158 4.0 0.2
25 6 16.0 51.9 13.3 0.3 15.4 12.2 79.0 4.0 49.5 37.5 + — 2.8 467 6.5 1.9
Abbreviations are: Bone area, mineralized bone plus osteoid; Ost/s, osteoid surface as % total bone surface; T/S, tetracycline surface as % bone
surface; OC, osteoclasts/mm bone surface; OST, average osteoid width in /2m; OST/a, osteoid area as % of bone area; BAC, bone aluminum
content; AI/s, aluminon surface as % bone surface; ASA/s, ASA surface as % bone surface; ASAJa, ASA area as % bone area; Iron, iron staining
in either marrow (m) or bone (b); DLT, double tetracycline labelled surfaces; BFR, bone formation rate; MLT, mineralization lag time; AR,
appositional rate.
Group 1-normal bone; Group 2-hyperparathyroid; Group 3-osteomalacia; Group 4-aplastic; Group 5-mixed hyperparathyroid & osteomalacia;
Group 6-abnormal, non-specific.
values have not been used for the correlation coefficients in group, nevertheless the aluminon surface staining was much
Table 2 but are included in the overall data in Table 1. Water for less. ASA area gave similar results to the surface measurement.
dialyzate contained less then 10 g!liter aluminum in this area Correlation coefficients for the subjects were the same which-
but was subsequently treated by reverse osmosis followed by ever of the three referents were used for comparison of alumi-
deionization, non and measured bone aluminum content, 0.726. (This is
similar to our findings in a previous study using 44 sample pairsResults [10]). ASA staining was the same when expressed as percent
Morphometty surface, but expressed as percent bone area a closer relation-
In Table 1 the histomorphometric groupings of all subjects ship was found, r 0.892, Table 2. As shown in Figure 1 the
are shown together with the means for each group. Excluding line of identity was displaced upwards on the ordinate showing
groups 1 and 6, where there was only a single subject in each that more surface staining was given by the ASA stain than with
group, the BAC was high in all groups. Nevertheless, the aluminon. The clinical data on the three starred patients in
aluminon surface staining varied between Groups 2 to 5, from a Figure 1 is as follows.
low of 9.3% in the aplastic group to a high of 48.5% in the Case 7, a 74-year-old female, developed aluminum intoxica-
osteomalacic, P < 0.001. The ASA surface was quite different tion from oral aluminum hydroxide prior to commencing dialy-
with 63.8% staining in the aplastic group and 74.5% in the sis. For the subsequent three years until she died she was not
osteomalacic. Although the BAC was as high, or higher, in the exposed to aluminum. Prior to parathyroidectomy a bone
hyperparathyroid and aplastic group as in the osteomalacic biopsy showed only 4% of surface positive for aluminon (Fig.
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Table 2. Table of correlations
Bone
area Ost/s T/s
OC/
mm
Ost
m
Ost/a
%
BAC
mg/k
Al/s
ASA!
s ASA/a
DLT
%
BFR
p.m2!
day!
mm2
MLT
day% %
% Osteoid surface (ost/s) 0.346
% Tetracycline surface (T/s) 0.132 0.124
Osteoclasts/mm bone (OC) 0.198 0.065 0.720
Osteoid width p.m (ost) 0.412 0.523 0.119 0.026
% Osteoid area/bone (ost!a) 0.303 0.709 0.150 0.095 0.943
Bone aluminum content mg/k (BAC) 0.444 0.253 0.332 0.029 0.389 0.284
% Aluminon surface (AIls) 0.062 0.394 0.599 0.398 0.268 0.364 0.726
% ASA surface (ASA/s) 0.234 0.274 0.539 0.119 0.249 0.292 0.726 0.681
% ASA area (ASA/a) 0.014 0.091 0.472 0.108 0.068 0.107 0.892 0.665 0.828
% Double label tetracycline (DLT) 0.301 0.107 0.761 0.621 0.045 0.103 0.015 0.388 0.345 0.202
Bone formation rate (BFR) pn2/ 0.330 0.083 0.756 0.462 0.091 0.165 0.044 0.462 0.424 0.340 0.872
day/mm2
Mineralization lag time (MLT) day 0.024 0.172 0.401 0.396 0.199 0.204 0.197 0.308 0.140 0.135 0.131 0.004
Apposition rate (AR) p.m/day 0.006 0.157 0.334 0.261 0.301 0.339 0.287 0.399 0.319 0.308 0.475 0.514 0.126
Abbreviations are in Table 1 legend.
a N 14; for all other parameters N = 25.
aluminum intake was approximately 3.1 kg. Bone biopsy prior
to possible parathyroidectomy for severe hyperparathyroidism
showed only 4% surface by aluminon but 37% as ASA area
(Fig. 5 A and B). Marrow cells were positive by both methods.
Bone aluminum content was 79 mg/kg.
Embedding plastic
Methyl methacrylate. This gave similar staining to GMA.
Spurr. ASA gave considerable background pink staining but
aluminum deposition could still be identified.
Physico-chemical factors. Heat. Sections that stained
strongly with aluminon were unaffected, but those where the
staining was negative or slight showed enhancement by heat
pre-treatment (Fig. 6 A and B). This effect was seen with all
three plastics and still occurred if the plastic was removed prior
to staining, The effect was seen by six hours and was maximal
after 12 to 18 hours. Deeper staining was also seen with ASA
100 following heat treatment but was not considered necessary.
Buffer pH. This was important for good aluminon staining. A
decrease in acidity reduced staining intensity.
Reaction temperature. No difference was observed in alumi-
non staining intensity between 37°C for two hours and 68°C for
10 minutes.
Discussion
2A), while the ASA showed 43% by area (Fig. 2B). Bone
aluminum content was elevated to 111 mg/kg. Four weeks after
the biopsy and parathyroidectomy she died unexpectedly from
endocarditis. Bone aluminum content was now 92 mg/kg and
both aluminon and ASA were strongly positive (Fig. 3 A and B).
Case 22, a healthy 51-year-old priest, was on home hemodi-
alysis from 1979 to 1983, 3.25 years, during which time he
consumed 9 kg of aluminum as aluminum hydroxide. Biopsy in
1983 showed 1% surface staining with aluminon although pos-
itive marrow cells could be seen. The ASA was strongly
positive at 27% (Fig. 4 A and B). Bone aluminum content was
75 mg/kg.
Case 25, a chronically ill 70-year-old male, had been on
continuous ambulatory peritoneal dialysis for seven years. His
Our findings show that while aluminon is a useful method for
detecting bone aluminum, it underestimates the amount present
and false negative results can occur. Faugere and Malluche
noted that bone aluminum content was elevated in all 55
patients in their study, but only 26 showed aluminon staining, a
false negative rate of 53% [6]. A recent review of the technique
came to similar conclusions [11]. De Vernejoul eta! [12] looked
at aluminon staining in relation to deferoxamine (DFO) chal-
lenge and found that with a similar rise in serum aluminum after
DFO infusion, aluminon staining varied from nil to extensive.
We commented in 1983 that when considering aluminum stor-
age in bone "the content of both marrow and bone should be
assessed" [9]. The presence of positive marrow cells in this
series would have been a clue to the presence of more alumi-
.
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Fig. 1. Relationship between surface staining with either the aluminon
or ASA stain. Note the upward displacement of the regression time.
Starred patients are described in the text.
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Figs. 2, 3. Comparison between sections stained with aluminon or ASA. Arrows point to positive staining. Case 7—Before parathyroidectomy: 2A
Aluminon, 2B ASA. After parathyroidectomy: 3A Aluminon, 3B ASA.
num than indicated by the trabecular aluminon staining. The
data of Denton et a! [8], confirmed by the present work,
suggests that ASA is more reliable than aluminon as a routine
method, particularly if chemical confirmation is not available.
The reason for the difference between the two techniques is
probably related to the more extensive decalcification with the
ASA method, thereby unmasking metal that, at times, may be
inaccessible to aluminon [8]. Heat possibly acts similarly. The
marrow staining in the absence of bone staining would be in
accord with this view.
The aluminon stain is technically more demanding and small
differences in buffer pH can be critical. The effect of heat
suggests that a physico-chemical change in the bone has oc-
cuned so that the metal is more readily accessible to the stain.
Uniformity between plastics and the lack of effect of MMA
removal indicates a direct effect of heat on mineralized bone.
Similarly, the adequate staining in the osteomalacic group
where mineralization failure is characteristic would suggest that
the physico-chemical characteristics of the bone mineral sur-
face determines the aluminon staining, independent in part, of
the amount of aluminum present.
It could be claimed that as the surface aluminum, particularly
that associated with osteoid, is responsible for the functional
defects in mineralization [6], then intra-trabecular staining is of
little or no consequence. The surface deposition of aluminum is
probably a critical determinant of bone mineralization as shown
by this and previous studies [13]. However, the extent of
surface staining may be inaccurate as in Groups 2 and 4 and
illustrated in the examples, plus the evaluation of the total bone
content would be essential if considering parathyroidectomy or
the safety of continued aluminum ingestion. These questions
may not be reliably and consistently answered with the alumi-
non technique.
Although trabecular and cortical bone do no necessarily
respond similarly [14, 15], we have consistently obtained a
close relationship between trabecular surface aluminum using
the aluminon stain and measured cortical bone aluminum [10].
This was confirmed in the present series and was also present
using the ASA stain.
Summary
Fourteen individuals on long term hemodialysis, with varying
amounts of aluminum in bone from 11 to 296 mg/kg by flameless
atomic absorption spectrophotometry, were examined to see
whether the aluminon or acid solochrome azurine (ASA) stain-
ing reactions best approximated the chemical determination.
Correlation coefficients were 0.78 for aluminon and 0.88 for
ASA. Together with 11 additional patients morphometric pa-
.4
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Figs. 4, 5. Comparison between sections stained with aluminon or ASA. Arrows point to positive staining. Case 22—4A Aluminon, 4B ASA. Case
25—5A Aluminon, 5B ASA.
Fig. 6. Effect of heat on aluminon staining. Arrows point to positive staining. A. Unheated; B heated.
rameters were compared with the two aluminum stains. The
aluminon stain gave satisfactory results in the osteomalacic
group but underestimated the amount of aluminum present in
those with hyperparathyroid, mixed or aplastic disease. Some
individuals showed a striking difference between the two tech-
niques which could have led to an erroneous conclusion regard-
ing the amount of aluminum present. The aluminon stain was
pH dependent and together with ASA could be enhanced by
prior heat treatment of the sections. It is recommended that
ASA either replace aluminon for routine use or be used together
with the alumjnon stain, particularly for bones without osteo-
malacia or with mild to moderate aluminum storage.
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